Methods and Compositions for Preventing Type 1 Diabetes
AssigneeProvention Bio, Inc.
InventorsFrancisco Leon, Kevan C. Herold, Jay S. Skyler
Life of this patent
Estimating the term…
Abstract
Provided herein, in one aspect, is a method of preventing or delaying the onset of clinical type 1 diabetes (T1D), comprising: providing a non-diabetic subject who is at risk for T1D; determining that the non-diabetic subject (1) is substantially free of antibodies against zinc transporter 8 (ZnT8), (2) is HLA-DR4+, and/or (3) is not HLA-DR3+; and administering a prophylactically effective amount of an anti-CD3 antibody to the non-diabetic subject.
Claims22
A method of preventing or delaying the onset of clinical type 1 diabetes (T1D), comprising:
- providing a non-diabetic subject who is at risk for T1D;
- determining that the non-diabetic subject (1) is substantially free of antibodies against zinc transporter 8 (ZnT8), (2) is HLA-DR4+, and/or (3) is not HLA-DR3+;
- and
- administering a prophylactically effective amount of an anti-CD3 antibody to the non-diabetic subject.
A method of prognosing responsiveness of an anti-CD3 antibody in preventing or delaying the onset of type 1 diabetes (T1D), comprising:
- providing a non-diabetic subject who is at risk for T1D;
- administering a prophylactically effective amount of an anti-CD3 antibody to the non-diabetic subject;
- and
- determining, by flow cytometry, a frequency of TIGIT+KLRG1+CD8+ T-cells in peripheral blood mononuclear cells of the non-diabetic subject, wherein an increase in the frequency indicates responsiveness to the anti-CD3 antibody.
Dependencies are inferred from the claim text.